MCM
ADCT icon

MAI Capital Management’s ADC Therapeutics ADCT Stock Holding History

MAI Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29
Closed -$109 – 2141
2026
Q1 		$109 Buy
29
+13
+81% +$51 ﹤0.01% 4744
2025
Q4 		$57 Buy
+16
New +$65 ﹤0.01% 4222

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MAI Capital Management's ADCT Position: Q2 2026 in Review

MAI Capital Management sold out of ADC Therapeutics (ADCT) in Q2 2026, closing a stake of 29 shares — an estimated $109 sold.

MAI Capital Management first reported a position in ADCT in Q4 2025 and held it in 2 quarters. The position peaked at $109 in Q1 2026. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • MAI Capital Management reported no remaining ADC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 29 ADC Therapeutics shares in Q2 2026, an estimated $109.
  • MAI Capital Management first reported a position in ADC Therapeutics in Q4 2025 and held it in 2 quarters.
  • MAI Capital Management's ADC Therapeutics position peaked at $109 in Q1 2026.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.